Company profile: Inhibikase Therapeutics
1.1 - Company Overview
Company description
- Provider of cellular Abelson tyrosine kinase inhibitor therapeutics and platforms for infections and other diseases. Includes Risvodetinib (IkT-148009), an oral drug aimed at halting and reversing Parkinson’s progression in brain and GI; IkT-001Pro, a prodrug of imatinib mesylate for blood and stomach cancers with fewer on-dosing side effects; IkT-01427 to prevent PML; and the RAMP Drug Innovation Engine and Prodrug Delivery Technology.
Products and services
- IkT-001Pro: Prodrug-based formulation of imatinib mesylate engineered to improve patient experience with fewer on-dosing side effects in blood and stomach cancers
- RAMP Drug Innovation Engine: Proprietary platform that architects novel small-molecule kinase inhibitors by preserving template drug properties while improving potency and safety
- Risvodetinib (IkT-148009): Custom-engineered oral medication aimed at halting progression and reversing functional loss in Parkinson’s disease across brain and gastrointestinal tract
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Inhibikase Therapeutics
Insmed
HQ: United States
Website
- Description: Provider of biopharmaceutical medicines for rare diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Insmed company profile →
Ondine Biomedical
HQ: Canada
Website
- Description: Provider of non-antibiotic, anti-infective therapies for bacterial, viral, and fungal infections, including Steriwave nasal decolonization that eradicates pathogens in minutes (MRSA, SARS-CoV-2), Photodisinfection using a photosensitive agent and non-thermal laser light to destroy pathogens without resistance, and an Expanded Access Program for investigational medicines prior to regulatory approval.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Ondine Biomedical company profile →
Rational Vaccines
HQ: United States
Website
- Description: Provider of pre-clinical live-attenuated herpes simplex virus vaccines.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Rational Vaccines company profile →
Coulter Pharmaceutical
HQ: United States
Website
- Description: Provider of immunotherapeutics aimed at treating and preventing autoimmune diseases, cancer, and infectious diseases by understanding and directing the immune system; conducted preclinical development programs including the BEXXAR therapy and MELACINE vaccine.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Coulter Pharmaceutical company profile →
NanoView Biosciences
HQ: United States
Website
- Description: Provider of proprietary products supporting research, translation and delivery of precision medicine, built on a novel platform that uniquely identifies and characterizes exosomes. Offers high-throughput, cost-effective analysis, including Leprechaun for lentivirus and exosome biophysical characterization, contaminant detection, and concentration measurement using fluorescence and antibody-based methods.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full NanoView Biosciences company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Inhibikase Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Inhibikase Therapeutics
2.2 - Growth funds investing in similar companies to Inhibikase Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Inhibikase Therapeutics
4.2 - Public trading comparable groups for Inhibikase Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →